Role of NMR in High Ordered Structure Characterization of Monoclonal Antibodies

Yuji Tokunaga 1,2 and Koh Takeuchi 1,2,*

Abstract: Obtaining high ordered structure (HOS) information is of importance to guarantee the efficacy and safety of monoclonal antibodies (mAbs) in clinical application. Assessment of HOS should ideally be performed in a non-invasive manner under their formulated storage conditions, as any perturbation can introduce unexpected detriments. However, most of the currently available techniques only indirectly report HOS of mAbs and/or require a certain condition to conduct the analyses. Besides, the flexible multidomain architecture of mAbs has hampered atomic-resolution structural analyses using X-ray crystallography and cryo-electron microscopy. In contrast, the ability of nuclear magnetic resonance (NMR) spectroscopy to structurally analyze biomolecules in various conditions in a non-invasive and quantitative manner is suitable to meet the needs. However, the application of NMR to mAbs is not straightforward due to the high molecular weight of the system. In this review, we will discuss how NMR techniques have been applied to HOS analysis of mAbs, along with the recent advances of the novel 15N direct detection NMR strategy that allows for obtaining the structural fingerprint of mAbs at lower temperatures under multiple formulation conditions. The potential application of these NMR strategies will benefit next-generation mAbs, such as antibody-drug conjugates and bispecific antibodies.

Keywords: NMR; high ordered structure; monoclonal antibodies; multi domain; formulation condition; 15N-direct detection

1. Introduction

Advancements in biotechnology have expanded the pharmacological modalities beyond the conventional small molecules. The expansion provides an opportunity to establish a novel strategy to target diseases, even for those which have been difficult to cure. Among such new modalities, biologics, especially therapeutic monoclonal antibodies (mAbs), have been utilized more extensively in clinics over the last decade. There is a nearly three-fold increase in the number of therapeutic mAbs on the market in 2019, as compared to 2010, and more than 600 mAbs are currently in commercial clinical pipelines [1].

Most therapeutic mAbs are IgG1, representing the most abundant and most extensively studied subclass of human IgG. IgG1 is a tetrameric protein consisting of two heavy chains with V\textsubscript{H}, CH\textsubscript{1}, CH\textsubscript{2}, and CH\textsubscript{3} domains, and two light chains with V\textsubscript{L} and C\textsubscript{L} domains. Structurally, V\textsubscript{H}, CH\textsubscript{1}, V\textsubscript{L}, and C\textsubscript{L} domains together form a Fab portion (Figure 1). On the other hand, two CH\textsubscript{2} and two CH\textsubscript{3} domains form an Fc portion. Thus, IgG1 also has dynamic nature as a multidomain protein. Fab is responsible for specific high-affinity binding to antigens, whereas the Fc region mediates immune response and effector functions. Fab and Fc fragments are connected by a hinge region, which is composed of 23 a.a. residues (216-EPKSDKTHHTCPPCPAPELLGGP-238). The two heavy chains are connected by two disulfide bridges, Cys-226 and Cys-229, at the hinge. A disulfide bridge at Cys-220 connects the light chain and heavy chain. The former half of the hinge provides flexibility...
to Fab, allowing IgG1 to bind to multiple antigens simultaneously. Currently, advances in protein engineering allow for constructing bispecific antibodies, which can target two different epitopes using different Fabs in a single IgG [2]. Taking advantage of the multivalent nature, bispecific antibodies have been extensively utilized in clinical applications.

Figure 1. Schematic representation of the structure of IgG. An IgG consists of two heavy chains (yellow) and two light chains (red). The \( V_H \) and \( CH_1 \) domains from a heavy chain interact with a light chain to form a Fab portion, while \( CH_2 \) and \( CH_3 \) domain dimer forms Fc portion. Fab and Fc portions are connected by the hinge region, where multiple conserved disulfide bridges are present. \( CH_2 \) domain has a conserved N-glycosylation site.

The Fc portion, in contrast, is indispensable for antibody effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), through Fc-FcγR and Fc-Complement 1q (C1q) interactions [3]. The Fc portion is basically composed of two identical \( CH_2 \) and \( CH_3 \) domains, which are related to each other by a two-fold axis. Thus, each Fc portion has been considered to bind up to two FcγR molecules. Indeed, two X-ray crystal structures suggested the 1:2 stoichiometry interactions, albeit the proposed models of the IgG-FcγR interactions are controversial [4,5]. Structural characterization by solution NMR, along with other biophysical methods, however, revealed that the stoichiometry of the interaction is 1:1 in reality. The binding of FcγR onto one of the two symmetrically related sites on the Fc region induces a conformational change in the other site to prevent the binding of another FcγR [6]. This fact clearly represents the importance of characterizing the interaction and structure of mAbs in physiological solutions.

High ordered structures (HOSs) of mAbs are critical in clinical applications, as these are directly reflected in their bioactivity [7]. The HOS of the biologics can be compromised by partial denaturation, aggregation, and chemical alterations. Tertiary structures of the biologics can be affected by the difference in expression, purification, formulation, and storage conditions, and the undesired HOS of mAbs often reduces their efficacy and causes unexpected adverse effects. Therefore, biophysical assays to analyze their HOS should be performed throughout the research and development phases to avoid such issues. In such a circumstance, assessing the HOS under their formulated storage conditions is essential to ensure the bioactivity and safety of a mAb. Such an analysis should ideally be performed in a non-invasive manner, as any perturbation of the sample can introduce undesired or unexpected defects to the system.

In addition, mAb has posttranslational modifications (PTMs), such as glycosylation. Each of the \( CH_2 \) domains possesses one N-linked oligosaccharide site at Asn-297 (Figure 1), and some also have glycosylation at Fab. The compositions of sugar chains are sensitive to production conditions and can modulate the stability, bioactivity, and immunogenicity
of the biologics [8,9]. Thus, quantitative analysis of the PTM states of the intact biologics is also important in structural evaluation. The Fc glycosylation of IgG is also critical to antibody effector functions [3]. Optimization of Fc glycosylation has been explored to enhance the ADCC activity of therapeutic mAbs, and a high degree of galactosylation can promote activation of CDC and have modest effects on ADCC [10,11]. It is also known that decreases in fucose levels lead to an increased affinity of IgG1 to FcγR, and an enhancement of ADCC activity [12]. The glycoform-dependent conformational changes of the Fc portion of IgG have been extensively analyzed by solution NMR [13]. It has been shown that the trimming of the carbohydrate residues results in the structural perturbation in the CH2 domains as well as a part of the lower hinge region, including the FcγR-binding site, where there is no direct contact with the sugar chain. These results indicate that the sugar chain is an integrated part of the IgG structure and is required for maintaining the structural integrity of the FcγR-binding site. It should be noted that, with sophisticated stable isotope labeling, NMR has been contributing to direct analysis of the structure and dynamics of sugar chains in IgG [14,15].

To characterize HOS of mAbs, biochemical and biophysical strategies, such as H/D-exchange mass spectrometry, differential scanning calorimetry, size exclusion chromatography, light scattering, and scanning electron-assisted dielectric microscopy, etc., have been utilized [16–18]. Several spectroscopic strategies, such as near- and far-UV circular dichroism, Raman, and Fourier-transform infrared, have also been used to evaluate the tertiary structures of the biologics [19–21]. However, these techniques often only indirectly report HOS of mAbs and require a certain condition to conduct these analyses. Although atomic-resolution structures of the biologics can be obtained by X-ray crystallography or cryo-electron microscopy, the requirement for crystallization or freezing procedures potentially modulates their tertiary structures. In addition, due to the flexible domain arrangements in intact mAb, only limited atomic-resolution structural information is available for full-length mAbs, and these structures can be only a single snapshot of the multiple conformations that exist in solution [22]. Therefore, a strategy that allows a non-invasive evaluation of the tertiary structures of the biologics is needed and, especially, those able to detect rarely populated structural states that can cause deterioration or side effects.

Nuclear magnetic resonance (NMR) spectroscopy offers a unique opportunity to non-invasively obtain structural information of the biologics under their formulated conditions, as it permits the structural analysis of biomolecules in various solutions [23–32]. As has already been discussed in the interaction between the Fc portion of IgG and FcγR, it is of importance to characterize the proteins in solution to gain a correct view of the systems. In this review, we will discuss how NMR has been utilized in biophysical and structural characterization of mAbs, along with the recent advances of the novel 15N direct detection NMR strategy that allows one to obtain the structural fingerprint of intact mAbs at a wide range of temperatures and formulations.

2. Use of 1H-Detected 1-Dimensional NMR to Characterize mAbs

Since the chemical shifts and line shapes of proton resonances are sensitive to the structure and dynamics of each position, the simplest 1H-detected 1-dimensional (1H-1D) NMR spectrum should reflect changes in HOS of a mAb. However, the application of 1H-1D NMR to a formulated mAb is not straightforward. Since most of the formulated conditions contain additives such as sugar, amino acids, and surfactants, the NMR spectra are overlapped with much stronger signals from these formulation components. In addition, severe line broadenings due to large molecular weight of mAb impair characteristics in the 1H NMR spectrum and small changes in HOS can be masked by the major of unaffected part of the mAb. Thus, additional tricks are usually applied to enhance the difference between mAbs. For example, in the PROtein FIngerprint by Line shape Enhancement (PROFILE) method [33], differences in the translational diffusion rates between large antibodies and small formulation components are exploited to distillate a 1H-1D spectrum of the mAb. Then, the featureless component in the spectrum is removed by subtracting
the artificially broadened spectrum to yield a PROFILE spectrum, which mostly contains unique components in the mAb spectrum. It is shown that the spectral correlation analysis of the PROFILE spectra can discriminate a pair of mAbs with different sequences and, even, the same mAb in different formulations [33]. Besides, it has been proposed that efficient spin-diffusion among protons in the protein’s structured regions can be utilized for selective detection of HOS components in the mAb NMR spectra [34].

$^1$H-1D NMR is also useful in monitoring the reversible self-association of mAbs, which can be the first step toward irreversible events, such as aggregation and liquid–liquid phase separation [35,36]. It has been shown that the mAb signal intensity in $^1$H-1D NMR spectra reflects the size of transient protein clusters and/or overall solution viscosity [35,36]. When two different mAbs, rituximab and infliximab, are compared, the infliximab gave lower S/N, which might be due to its tendency to form reversible oligomers [37]. In addition, translational diffusion coefficients and transverse relaxation rates can be measured to analyze these factors more quantitatively.

It should be noted that $^1$H-detected 1D NMR experiments are also used to analyze the interaction between formulation components and biologics [38]. Finding formulations to provide sufficient stability during long-term storage is important in developing a therapeutic mAb. For this purpose, saturation transfer difference NMR (STD-NMR) spectroscopy was used to assess the interactions of formulation components with mAb to understand the mechanism of stability enhancements by these additives [38].

3. Use of Heteronuclear-Detected 1D NMR for Structural Characterization of mAb

The heteronuclear-detected 1D NMR of a mAb has a long-standing history. Already in the late 1980s, Arata and co-workers have shown that specific detection and assignment of mAb signals is possible for intact IgGs, using carbonyl $^{13}$C direct-detection NMR spectroscopy [39], along with double-labeling techniques [40,41]. By growing mammalian cells in a serum-free medium, the authors have successfully introduced [1-$^{13}$C] Met into a mouse mAb and established the complete assignment of Met carbonyl $^{13}$C resonances. The strategy was expanded to the carbonyl carbons of Trp, Tyr, His, and Cys residues, and used for the structural analyses of antigen binding, domain–domain interactions [42], and dynamics of the hinge region [43]. These strategies are fundamental to the multinuclear approach of mAb NMR spectroscopy [44].

Large self-associated species of mAb are no longer visible in a conventional NMR spectrum. However, such an NMR-invisible state can be accessible by using the dark-state exchange saturation transfer (DEST) NMR techniques [45,46]. In the DEST experiment, the saturation of the invisible “dark” state is transferred to the NMR visible state by an exchange between visible and invisible states, leading to signal attenuation. Using two differentially $^{19}$F-labeled mAbs [47], the temperature-dependent formation of protein-specific clusters was assessed at high concentrations (up to 400 mg/mL) [48]. The strategy would be useful in studying mAb mixtures to see if there are any reversible aggregation/oligomerization that are not readily detected in other experimental strategies.

4. Obtaining Structural Fingerprint by $^1$H-Detected Multidimensional NMR

The 1D experiments are more sensitive in general; however, site-specific detection of resonances is not straightforward, without introducing the additional trick such as specific labeling and/or extensive post-acquisition processing. In contrast, multidimensional NMR spectra can offer a comprehensive fingerprint of a protein, in which most of the sites are individually resolved in the spectrum. Especially, the application of two-dimensional (2D) heteronuclear $^1$H,$^{15}$N- or $^1$H,$^{13}$C-correlated spectroscopy to the characterization of HOS of mAb has generated great interest.

However, the application of multidimensional NMR methods to intact mAbs is a significant challenge due to short transverse relaxation times due to slow molecular tumbling. For such large molecular weight systems, the deuteration of nonlabile $^1$H sites and use of transverse relaxation optimized spectroscopy (TROSY) or cross-correlated relaxation-
enhanced polarization transfer (CRINEPT) are commonly employed to overcome the rapid transverse relaxation [49,50]. Although heterologous expression of mAbs in *Escherichia coli* is possible to achieve high-level deuteration, mAbs obtained in this approach do not retain mammalian-type glycosylation. In contrast, using mammalian cell lines, appropriately glycosylated mAbs can be produced [15]; however, high-level deuteration is difficult as these cells cannot grow in such conditions.

The general strategy to obtain the 2D NMR spectra of mAb is to use high temperatures to accelerate the molecular tumbling (Figure 2; upper). In addition, fragmentation of intact IgG into Fab and Fc portions is also widely used to reduce the molecular weight. Indeed, almost complete assignment of the Fc region is reported in such a condition [51]. Currently, high-temperature recording at natural isotopic abundance is possible for both $^{13}$C and $^{15}$N [52], with the implementation of high-sensitive cryogenic probe technology [53] and the utilization of rapid acquisition methods, including selective optimized flip angle short transient (SOFAST) pulse schemes [54] and the non-uniform sampling (NUS) [55,56]. It is reported that more than 95% of mAb $^1$H$^{13}$C methyl resonances can be observed in a spectrum acquired in 12 h at 900 MHz and 50 °C [52]. The sample concentration was limited to be <300 µM due to increases in sample viscosity at higher concentrations. At 600 MHz, a 2D $^1$H$^{13}$C NMR methyl fingerprint spectrum was also be acquired; however, a reduction in the spectral resolution was reported. As for 2D $^1$H$^{15}$N correlation spectra, a SOFAST–heteronuclear multiple quantum correlation (HMQC) spectrum of NISTmAb was obtained with a total experimental duration of approximately 68 h at 900MHz and 50 °C [57]. Such spectra have been shown to have the ability to distinguish the different mAbs [57], different glycosylation states [57,58], the effect of additives [59], and chemical modifications [60,61]. In most cases, however, Fab and Fc fragments were used for detailed analyses [62]. It was reported that Fc and Fab fragments yielded methyl fingerprint spectra in a much shorter time in approximately 30 min [52]. It should be noted that an international effort of standardization to make the 2D NMR method a highly confident routine way to assess HOS of mAb is underway [63–66].

![Figure 2. Application of conventional 2D $^1$H-$^{15}$N correlation experiments to mAb. The spectra were recorded at (top) 32 °C and (bottom) 4 °C for an intact $^{15}$N-Ala] IgG. For each condition, the $^1$H-detected TROSY (left), $^1$H-detected CRINEPT (middle), and the $^{15}$N-detected TROSY (right) were recorded. For $^1$H-detected spectra, the $^1$H and $^{15}$N axes of the spectra are transposed as indicated by arrows. The figure is reproduced from [67].](image)

5. The $^{15}$N-Detected CRINEPT for the HOS Analysis of a mAb under Formulated Storage Conditions

As mentioned above, $^1$H-detected multidimensional NMR experiments allow site-specific observation of mAbs at high temperature. Measuring at higher temperature, however, possibly induces the deterioration and aggregation of the biologics, due to
structural and chemical heterogeneity of mAbs that might not exist at lower temperatures. In addition, the aforementioned experiments yield almost no signal at 4 °C [67] (Figure 2; bottom). This is simply because a slower tumbling of mAbs at lower temperatures enhances the transverse relaxation of NMR coherences. At typical storage temperature (4 °C), the rotational correlation time (τc) of proteins is estimated to be two-fold greater than at 32 °C. This means that a mAb behaves like a 300 kDa protein at 4 °C. Therefore, a strategy to measure the mAb NMR signals at a wider range of temperatures, including low storage temperature, and under various formulation conditions is required.

We recently developed a novel 15N-direct detection NMR experiment, 15N-detected CRINEPT, which allows high-sensitive and high-resolution measurements of non-deuterated high molecular weight proteins (Figure 3A). The principles of the coherence transfer in the 15N-detected CRINEPT is the same as in the 1H-detected CRINEPT [68]; however, for high-sensitive detection, several tricks are introduced, such as the concatenation of the 1H-chemical shift evolution and the 1H to 15N coherence transfer periods, and the 15N-direct detection of antiphase coherence. For a 150 kDa protein at 4 °C, the sensitivity of the 15N-detected CRINEPT was expected to be >20-fold greater than that of the previously reported insensitive nuclei enhanced by polarization transfer (INEPT)-based experiment [69,70]. Since the 15N transverse relaxation rate is less sensitive to the presence of remote protons, the direct 15N-detection scheme employed in the experiment does not require protein deuteration. This feature is essential for evaluating the HOS of biologics that are mostly obtained from mammalian cells. This technique was applied to an intact mAb at a wide range of temperatures (4–32 °C) and formulation conditions, including those used for long-term storage, for subcutaneous injection (SC), and intravenous injection (IV). These formulation conditions contain amino acids, surfactants, and sugars (Figure 3B), however, any of these additives do not yield unwanted signals in 15N-detected CRINEPT spectrum. Using the 15N-detected CRINEPT technique, a large fraction of 1H-15N correlation signals of mAbs was successfully observed under formulated storage conditions; where conventional 1H- and 15N-detected experiments do not work (Figure 3C).

The spectral patterns of mAbs in different formulation conditions were similar but not identical. This indicates that the mAb might take slightly different conformations in these formulations. It demonstrates that the 15N-detected CRINEPT is suitable to analyze the effect of additives to the HOS of mAbs. Especially, in SC and IV conditions, Ala-339 in the CH2 and CH3 domain linker showed different chemical shifts, indicating that the site is sensitive to the small difference in the formulation (Figure 4A). In addition, by using the 15N-detected CRINEPT spectra, the heterogeneity of galactosyl modifications at the tip of the N-linked sugar chain was quantitatively characterized in the intact mAb (Figure 4B). The resonance originating from Lys-248 seemed to consist of multiple components that were dispersed in the 15N dimension, reflecting the structural variation of mAb, depending on polymorphic glycosylation states. The glycosylation states quantified by NMR agreed with those estimated by liquid chromatography–mass spectrometry (Figure 4C). Therefore, the 15N-detected CRINEPT is suitable for a non-invasive HOS evaluation of the biologics.
Figure 3. Two-dimensional $^{15}$N-detected CRINEPT spectra of mAb in formulated storage condition. (A) The pulse sequence of the $^{15}$N-detected CRINEPT experiment. Narrow bars indicate $\pi/2$ hard pulses. The phase cycles employed were $\varphi_1 = (x-x)$, $\varphi_2 = y$, $\varphi_3 = (x-x-x-x)$, and $\varphi_{rec} = (x-x-x-x)$. Phase-sensitive acquisition in the indirect $^1$H dimension is achieved by incrementing the phase $\varphi_1$ in a STATES-TPPI manner [71]. (B) Examples of formulation condition for subcutaneous injection (SC; left), and intravenous injection (IV; right). (C) The $^{15}$N-detected CRINEPT spectra of the mAb in the SC (left) and IV (right) formulations. These spectra were acquired at 4 °C. The figure is reproduced from [67].
Figure 4. The HOS analysis of a mAb using a $^{15}$N-detected CRINEPT experiment. (A) Overlaid $^{15}$N-detected CRINEPT spectra of $[^{15}$N-Ala] mAb in SC (pink) and IV (blue) formulations. The assignments are based on the chemical shifts of the Ala resonances of the Fc fragment, as previously reported [51]. The structure of the Fc fragment (1H3Y) [72] is shown along with the positions of Ala residues. Signals from $^{15}$N TROSY components are labeled with numbers. (B) The heterogeneity of the galactosylation states analyzed by the $^{15}$N-detected CRINEPT experiment. Left: the $^{1}$H–$^{15}$N resonance of Lys-248 in the $^{15}$N-detected CRINEPT spectrum of the intact mAb is shown along with those from the ∆Gal (blue) and Gal (black) samples, which are enzymatically galactosidated and galactosylated, respectively. Right: ratios of different galactosylation states, estimated from the deconvolution of the Lys-248 resonance in the intact mAb. (C) Ratios of different galactosylation states by LC–MS analysis. Reflecting that the analysis cannot discriminate G0_G2 and G1_G1 states, each bar represents the upper and lower limits of the indicated population. The figure is reproduced from [67].

6. Future Perspectives

As discussed above, the structural characterization of mAbs by NMR is powerful in obtaining HOS information of mAb as well as their stability in formulation conditions. The multifaced information from NMR will further accelerate the research and development of future mAb therapeutics. In particular, the $^{15}$N-detected CRINEPT experiment will be useful in such analysis as it can be utilized in a wide range of conditions, including low-temperature storage conditions. In addition, next-generation mAbs such as antibody-drug conjugates and bispecific antibodies are developing [73,74]. Upon the chemical conjugation, a mAb can change its local structure, stability, and oligomerization states. Such information could readily be detected by multidimensional NMR experiments. In addition, the relative orientation of Fab would be important to define the arrangement of antigens to exert specific functions. The combination of the $^{15}$N-detected CRINEPT experiment with a residual dipolar coupling experiment, for example, might provide information that can define the relative orientation of the Fab in solution. Stable isotope labeling is practically useful; however, considering that the strict regulation of pharmaceutical production, utilization of an isotope-labeled amino acid in the production stage is not trivial. It should be also noted that the versatility of NMR would allow observing and analyzing IgG in its functional site,
such as in serum [75]. Nevertheless, the efforts to further expand the merit of NMR in the HOS analysis of mAbs would be important at various stages in research, development, and clinical applications.

**Author Contributions:** Writing—original draft preparation, K.T.; writing—review and editing, Y.T. and K.T. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Japan Society for the Promotion of Science, KAKENHI Grant Numbers JP19K07040 (to Y.T.), JP18K19415, JP20H03378, and JP20H04722 (to K.T.), and by Takeda Science Foundation.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

- NMR: Nuclear magnetic resonance
- HOS: High ordered structures
- mAb: Monoclonal antibody
- PTM: Posttranslational modification
- ADCC: Antibody-dependent cell-mediated cytotoxicity
- ADCP: Antibody-dependent cellular phagocytosis
- CDC: Complement-dependent cytotoxicity
- C1q: Complement 1q
- PROFILE: PROtein FIngerprint by Line shape Enhancement
- STD: Saturation transfer difference
- DEST: Dark-state exchange saturation transfer
- 2D: Two-dimensional
- TROSY: Transverse relaxation optimized spectroscopy
- CRINEPT: Cross-correlated relaxation-enhanced polarization transfer
- SOFAST: Selective optimized flip angle short transient
- HMQC: Heteronuclear multiple quantum correlation
- INEPT: Insensitive nuclei enhanced by polarization transfer
- NUS: Non-uniform sampling
- SC: Subcutaneous
- IV: Intravenous

**References**

1. Kaplon, H.; Muralidharan, M.; Schneider, Z.; Reichert, J.M. Antibodies to watch in 2020. *MAbs* 2020, 12, 1703531. [CrossRef]
2. Husain, B.; Ellerman, D. Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies. *BioDrugs* 2018, 32, 441–464. [CrossRef] [PubMed]
3. Reusch, D.; Tejada, M.L. Fc glycans of therapeutic antibodies as critical quality attributes. *Glycobiology* 2015, 25, 1325–1334. [CrossRef] [PubMed]
4. Sondermann, P.; Huber, R.; Jacob, U. Crystal structure of the soluble form of the human Fcγ-receptor IIb: A new member of the immunoglobulin superfamily at 1.7 Å resolution. *EMBO J.* 1999, 18, 1095–1103. [CrossRef] [PubMed]
5. Maxwell, K.F.; Powell, M.S.; Hulett, M.D.; Barton, P.A.; McKenzie, I.F.C.; Garrett, T.P.J.; Hogarth, P.M. Crystal structure of the human leukocyte Fc receptor, FcγRIIA. *Nat. Struct. Biol.* 1999, 6, 437–442. [CrossRef] [PubMed]
6. Kato, K.; Sautès-Fridman, C.; Yamada, W.; Kobayashi, K.; Uchiyama, S.; Kim, H.; Enokizono, J.; Galinha, A.; Kobayashi, Y.; Fridman, W.H.; et al. Structural basis of the interaction between IgG and fcy receptors. *J. Mol. Biol.* 2000, 295, 213–224. [CrossRef] [PubMed]
7. Beck, A.; Wagner-Rousset, E.; Ayoub, D.; Van Dorsselaer, A.; Sanglier-Cianferrani, S. Characterization of Therapeutic Antibodies and Related Products. *Anal. Chem.* 2013, 85, 715–736. [CrossRef]
8. Zhang, L.; Luo, S.; Zhang, B. Glycan analysis of therapeutic glycoproteins. *MAbs* 2016, 8, 205–215. [CrossRef]
9. Jefferis, R. Glycosylation of recombinant antibody therapeutics. *Biotechnol. Prog.* 2005, 21, 11–16. [CrossRef]
10. Hodoniczky, J.; Zheng, Y.Z.; James, D.C. Control of Recombinant Monoclonal Antibody Effector Functions by Fc N-Glycan Remodeling in Vitro. *Biotechnol. Prog.* 2005, 21, 1644–1652. [CrossRef]
11. Nimmerjahn, F.; Anthony, R.M.; Ravetch, J.V. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. *Proc. Natl. Acad. Sci. USA* 2007, 104, 8433. [CrossRef] [PubMed]

12. Okazaki, A.; Shoji-Hosaka, E.; Nakamura, K.; Wakitani, M.; Uchida, K.; Kakita, S.; Tsumoto, K.; Kumagai, I.; Shirata, K. Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcγRIIIa. *J. Mol. Biol.* 2004, 336, 1239–1249. [CrossRef] [PubMed]

13. Yamaguchi, Y.; Nishimura, M.; Nagano, M.; Yagi, H.; Sasakawa, H.; Uchida, K.; Shirata, K.; Kato, K. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. *Biochim. Biophys. Acta* 2006, 1760, 693–700. [CrossRef] [PubMed]

14. Yanaka, S.; Yagi, H.; Yogo, R.; Yagi-Utsumi, M.; Kato, K. Stable isotope labeling approaches for NMR characterization of glycoproteins using eukaryotic expression systems. *J. Biomol. NMR* 2018, 71, 193–202. [CrossRef] [PubMed]

15. Kato, K.; Yamaguchi, Y.; Arata, Y. Stable-isotope-assisted NMR approaches to glycoproteins using immunoglobulin G as a model system. *Prog. Nucl. Magn. Reson. Spectrosc.* 2010, 56, 346–359. [CrossRef] [PubMed]

16. Andersen, C.B.; Manno, M.; Rischel, C.; Thörn, L.; Thörn, L.; Martorana, V. Aggregation of a multidomain protein: A coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress. *Protein Sci.* 2010, 19, 279–290. [CrossRef]

17. Houde, D.; Engen, J.R. Conformational analysis of recombinant monoclonal antibodies with hydrogen/deuterium exchange mass spectrometry. *Methods Mol. Biol.* 2013, 988, 269–289. [CrossRef]

18. Seng, Y.; Imamura, H.; Ogura, T.; Honda, S. In-Solution Microscopic Imaging of Fractal Aggregates of a Stressed Therapeutic Antibody. *Anal. Chem.* 2019, 91, 4640–4648. [CrossRef]

19. Li, C.H.; Nguyen, X.; Narhi, L.; Chemmalil, L.; Towers, E.; Muzammil, S.; Gabrielson, J.; Jiang, Y. Applications of circular dichroism (CD) for structural analysis of proteins: Qualification of near- and far-UV CD for protein higher order structural analysis. *J. Pharm. Sci.* 2011, 100, 4642–4654. [CrossRef]

20. Boulet-Audet, M.; Byrne, B.; Kazarian, S.G. High-Throughput Thermal Stability Analysis of a Monoclonal Antibody by Attenuated Total Reflection FT-IR Spectroscopic Imaging. *Anal. Chem.* 2014, 86, 9786–9793. [CrossRef]

21. Thiagarajan, G.; Widjaja, E.; Heo, J.H.; Cheung, J.K.; Wabuyele, B.; Mou, X.; Shameem, M. Use of Raman and Raman optical activity for the structural characterization of a therapeutic monoclonal antibody formulation subjected to heat stress. *J. Raman Spectrosc.* 2015, 46, 531–536. [CrossRef]

22. Saphire, E.O.; Stanfield, R.L.; Crispin, M.D.; Parren, P.W.; Rudd, P.M.; Dwek, R.A.; Burton, D.R.; Wilson, I.A. Contrasting IgG structures reveal extreme asymmetry and flexibility. *J. Mol. Biol.* 2002, 319, 9–18. [CrossRef]

23. Quintermet, M.; Stark, J.-P.; Delsuc, M.-A.; Kieffer, B. Heteronuclear NMR provides an accurate assessment of therapeutic insulin’s quality. *J. Mol. Biol.* 2013, 78–79, 252–254. [CrossRef] [PubMed]

24. Ghasriani, H.; Hodgson, D.J.; Brinson, R.G.; McEwen, I.; Buhse, L.F.; Kozlowski, S.; Marino, J.P.; Aubin, Y.; Keire, D.A. Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars. *Nat. Biotechnol.* 2016, 34, 139–141. [CrossRef]

25. Amezgua, C.A.; Szabo, C.M. Assessment of Higher Order Structure Comparability in Therapeutic Proteins Using Nuclear Magnetic Resonance Spectroscopy. *J. Pharm. Sci.* 2013, 102, 1724–1733. [CrossRef]

26. Aubin, Y.; Gingras, G.; Sauvè, S. Assessment of the Three-Dimensional Structure of Recombinant Protein Therapeutics by NMR Fingerprinting: Demonstration on Recombinant Human Granulocyte-Macrophage-Colony Stimulation Factor. *Anal. Chem.* 2008, 80, 2623–2627. [CrossRef]

27. Chen, K.; Freedberg, D.I.; Keire, D.A. NMR profiling of biomolecules at natural abundance using 2D 1H–15N and 1H–13C multiplicity-separated (MS) HSQC spectra. *J. Magn. Reson.* 2015, 251, 65–70. [CrossRef]

28. Jin, X.; Kang, S.; Kwon, H.; Park, S. Heteronuclear NMR as a 4-in-1 Analytical Platform for Detecting Modification-Specific Signatures of Therapeutic Insulin Formulations. *Anal. Chem.* 2014, 86, 2050–2056. [CrossRef]

29. Levy, M.J.; Gucinski, A.C.; Sommers, C.D.; Ghasriani, H.; Wang, B.; Keire, D.A.; Boyne, M.T. Analytical techniques and bioactivity assays to compare the structure and function of filgrastim (granulocyte-colony stimulating factor) therapeutics from different manufacturers. *Anal. Bioanal. Chem.* 2014, 406, 6559–6567. [CrossRef]

30. Shah, D.D.; Singh, S.M.; Mallale, K.M.G. Effect of Chemical Oxidation on the Higher Order Structure, Stability, Aggregation, and Biological Function of Interferon Alpha-2a: Role of Local Structural Changes Detected by 2D NMR. *Pharm. Res.* 2018, 35, 232. [CrossRef]

31. Brinson, R.G.; Marino, J.P. 2D J-correlated proton NMR experiments for structural fingerprinting of biotherapeutics. *J. Magn. Reson.* 2019, 307, 106581. [CrossRef] [PubMed]

32. Pandya, A.; Howard, M.J.; Zloh, M.; Dalby, P.A. An Evaluation of the Potential of NMR Spectroscopy and Computational Modelling Methods to Inform Biopharmaceutical Formulations. *Pharmaceutics* 2018, 10, 165. [CrossRef] [PubMed]

33. Poppe, L.; Jordan, J.B.; Lawson, K.; Jerums, M.; Apostol, I.; Schnier, P.D. Profiling formulated monoclonal antibodies by 1H NMR spectroscopy. *Anal. Chem.* 2013, 85, 9623–9629. [CrossRef] [PubMed]

34. Franks, J.; Glushka, J.N.; Jones, M.T.; Live, D.H.; Zou, Q.; Prestegard, J.H. Spin Diffusion Editing for Structural Fingerprints of Therapeutic Antibodies. *Anal. Chem.* 2016, 88, 1320–1327. [CrossRef] [PubMed]

35. Kheddo, P.; Cliff, M.J.; Uddin, S.; van der Walle, C.F.; Golovarov, A.P. Characterizing monoclonal antibody formulations in arginine glutamate solutions using 1H NMR spectroscopy. *MAbs* 2016, 8, 1245–1258. [CrossRef] [PubMed]
36. Kheddo, P.; Bramham, J.E.; Dearman, R.J.; Uddin, S.; van der Walle, C.F.; Golovanov, A.P. Investigating Liquid–Liquid Phase Separation of a Monoclonal Antibody Using Solution-State NMR Spectroscopy: Effect of Arg-Glu and Arg HCl. *Mol. Pharm.* 2017, 14, 2852–2860. [CrossRef]

37. Chen, K.; Long, D.S.; Lute, S.C.; Levy, M.J.; Broxson, K.A.; Keire, D.A. Simple NMR methods for evaluating higher order structures of monoclonal antibody therapeutics with quinary structure. *J. Pharm. Biomed. Anal.* 2016, 128, 398–407. [CrossRef]

38. Svilenov, H.L.; Kulakova, A.; Zalar, M.; Golovanov, A.P.; Harris, P.; Winter, G. Orthogonal Techniques to Study the Effect of pH, Sucrose, and Arginine Salts on Monoclonal Antibody Physical Stability and Aggregation During Long-Term Storage. *J. Pharm. Sci.* 2020, 109, 584–594. [CrossRef]

39. Kato, K.; Matsunaga, C.; Nishimura, Y.; Waelchli, M.; Kainosho, M.; Arata, Y. Application of 13C nuclear magnetic resonance spectroscopy to molecular structural analyses of antibody molecules. *J. Biochem.* 1989, 105, 867–869. [CrossRef]

40. Kato, K.; Matsunaga, C.; Igarashi, T.; Kim, H.; Odaka, A.; Shimada, I.; Arata, Y. Complete assignment of the methionyl carbonyl carbon resonances in switch variant anti-dansyl antibodies labeled with [1-13C]methionine. *Biochemistry* 1991, 30, 270–278. [CrossRef]

41. Kainosho, M.; Tsuji, T. Assignment of the three methionyl carbonyl carbon resonances in Streptomyces subtilisin inhibitor by a carbon-13 and nitrogen-15 double-labeling technique. A new strategy for structural studies of proteins in solution. *Biochemistry* 1982, 21, 6273–6279. [CrossRef] [PubMed]

42. Kato, K.; Matsunaga, C.; Odaka, A.; Yamato, S.; Takaha, W.; Shimada, I.; Arata, Y. Carbon-13 NMR study of switch variant anti-dansyl antibodies: Antigen binding and domain-domain interactions. *Biochemistry* 1991, 30, 6604–6610. [CrossRef] [PubMed]

43. Matsunaga, C.; Kato, K.; Arata, Y. A 13C NMR study of the hinge region of a mouse monoclonal antibody. *J. Biomol. NMR* 1991, 1, 379–390. [CrossRef] [PubMed]

44. Arata, Y.; Kato, K.; Takahashi, H.; Shimada, I. [13C] Nuclear Magnetic Resonance Study of Antibodies: A Multinuclear Approach. In *Methods in Enzymology*; Academic Press: Amsterdam, The Netherlands, 1994; Volume 239, pp. 440–464.

45. Anthis, N.J.; Clore, G.M. Visualizing transient dark states by NMR spectroscopy. *Q. Rev. Biophys.* 2015, 48, 35–116. [CrossRef]

46. Fawzi, N.L.; Ying, J.; Torchia, D.A.; Clore, G.M. Probing exchange kinetics and atomic resolution dynamics in high-molecular-weight complexes using dark-state exchange saturation transfer NMR spectroscopy. *Nat. Protoc.* 2012, 7, 1523–1533. [CrossRef]

47. Edwards, J.M.; Derrick, J.P.; van der Walle, C.F.; Golovanov, A.P. 19F NMR as a Tool for Monitoring Individual Differentially Labeled Proteins in Complex Mixtures. *Mol. Pharm.* 2018, 15, 2785–2796. [CrossRef]

48. Edwards, J.M.; Bramham, J.E.; Podmore, A.; Bishop, S.M.; van der Walle, C.F.; Golovanov, A.P. 19F Dark-State Exchange Saturation Transfer NMR Reveals Reversible Formation of Protein-Specific Large Clusters in High-Concentration Protein Mixtures. *Anal. Chem.* 2019, 91, 4702–4708. [CrossRef]

49. Pervushin, K.; Riek, R.; Wider, G.; Wuthrich, K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. *Proc. Natl. Acad. Sci. USA* 1997, 94, 12366–12371. [CrossRef]

50. Tugarinov, V.; Hwang, P.M.; Ollersenshaw, J.E.; Kay, L.E. Cross-correlated relaxation enhanced 1H[bond]13C NMR spectroscopy of methyl groups in very high molecular weight proteins and protein complexes. *J. Am. Chem. Soc.* 2003, 125, 10420–10428. [CrossRef]

51. Yagi, H.; Zhang, Y.; Yagi-Utsumi, M.; Yamaguchi, T.; lida, S.; Yamaguchi, Y.; Kato, K. Backbone (1)H, (13)C, and (15)N resonance assignments of the Fc fragment of human immunoglobulin G glycoprotein. *Bioimol. NMR Assign.* 2015, 9, 257–260. [CrossRef]

52. Arbogast, L.W.; Brinson, R.G.; Marino, J.P. Mapping Monoclonal Antibody Structure by 2D 13C NMR at Natural Abundance. *Anal. Chem.* 2015, 87, 3556–3561. [CrossRef] [PubMed]

53. Kovacs, H.; Moskau, D.; Spraul, M. Cryogenically cooled probes—a leap in NMR technology. *Prog. Nucl. Magn. Reson. Spectros.* 2005, 46, 131–155. [CrossRef]

54. Schanda, P.; Kupce, E.; Brutscher, B. SOFAST-HMQC experiments for recording two-dimensional heteronuclear correlation spectra of proteins within a few seconds. *J. Biomol. NMR* 2005, 33, 199–211. [CrossRef] [PubMed]

55. Maciejewski, M.W.; Mobli, M.; Schuyler, A.D.; Stern, A.S.; Hoch, J.C. Data sampling in multidimensional NMR: Fundamentals and strategies. *Top. Curr. Chem.* 2012, 316, 49–77. [CrossRef]

56. Hyberts, S.G.; Arthanari, H.; Wagner, G. Applications of non-uniform sampling and processing. *Top. Curr. Chem.* 2012, 316, 125–148. [CrossRef]

57. Arbogast, L.W.; Brinson, R.G.; Formolo, T.; Hoopes, J.T.; Marino, J.P. 2D 1HN, 15N Correlated NMR Methods at Natural Abundance for Obtaining Structural Maps and Statistical Comparability of Monoclonal Antibodies. *Pharm. Res.* 2016, 33, 462–475. [CrossRef]

58. Arbogast, L.W.; Delaglio, F.; Schiel, J.E.; Marino, J.P. Multivariate Analysis of Two-Dimensional 1H, 13C Methyl NMR Spectra of Monoclonal Antibody Therapeutics to Facilitate Assessment of Higher Order Structure. *Anal. Chem.* 2017, 89, 11839–11845. [CrossRef]

59. Singh, S.M.; Bandi, S.; Jones, D.N.M.; Mallela, K.M.G. Effect of Polysorbate 20 and Polysorbate 80 on the Higher-Order Structure of a Monoclonal Antibody and Its Fab and Fc Fragments Probed Using 2D Nuclear Magnetic Resonance Spectroscopy. *J. Pharm. Sci.* 2017, 106, 3486–3498. [CrossRef]
60. Majumder, S.; Sattii, A.; Philip, S.; Liu, L.L.; Stephens, E.; Rouse, J.C.; Alphonse Ignatius, A. Utility of High Resolution NMR Methods to Probe the Impact of Chemical Modifications on Higher Order Structure of Monoclonal Antibodies in Relation to Antigen Binding. *Pharm. Res.* 2019, 36, 130. [CrossRef]

61. Hinterholzer, A.; Stanojlovic, V.; Cabrele, C.; Schubert, M. Unambiguous Identification of Pyroglutamate in Full-Length Biopharmaceutical Monoclonal Antibodies by NMR Spectroscopy. *Anal. Chem.* 2019, 91, 14299–14305. [CrossRef]

62. Hodgson, D.J.; Ghasriani, H.; Aubin, Y. Assessment of the higher order structure of Humira®, Remicade®, Avastin®, Rituxan®, Herceptin®, and Enbrel® by 2D-NMR fingerprinting. *J. Pharm. Biomed. Anal.* 2019, 163, 144–152. [CrossRef] [PubMed]

63. Brinson, R.G.; Marino, J.P.; Delaglio, F.; Arbogast, L.W.; Evans, R.M.; Kearsley, A.; Giddens, J.P.; Marino, J.P.; Pierens, G.K.; et al. Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics. *MAbs* 2019, 11, 94–105. [CrossRef] [PubMed]

64. Brinson, R.G.; Arbogast, L.W.; Marino, J.P.; Delaglio, F. Best Practices in Utilization of 2D-NMR Spectral Data as the Input for Chemometric Analysis in Biopharmaceutical Applications. *J. Chem. Inf. Modeling* 2020, 60, 2339–2355. [CrossRef] [PubMed]

65. Arbogast, L.W.; Brinson, R.G.; Marino, J.P. Chapter One—Application of Natural Isotopic Abundance 1H–13C- and 1H–15N-Correlated Two-Dimensional NMR for Evaluation of the Structure of Protein Therapeutics. In Methods in Enzymology; Kelman, Z., Ed.; Academic Press: Amsterdam, The Netherlands, 2016; Volume 566, pp. 3–34.

66. Brinson, R.G.; Elliott, K.W.; Arbogast, L.W.; Sheen, D.A.; Giddens, J.P.; Marino, J.P.; Delaglio, F. Principal component analysis for automated classification of 2D spectra and interferograms of protein therapeutics: Influence of noise, reconstruction details, and data preparation. *J. Biomol. NMR* 2020, 1–4. [CrossRef]

67. Tokunaga, Y.; Takeuchi, K.; Okude, J.; Ori, K.; Torizawa, T.; Shimada, I. Structural Fingerprints of an Intact Monoclonal Antibody Acquired under Formulated Storage Conditions via 15N Direct Detection Nuclear Magnetic Resonance. *J. Med. Chem.* 2020, 63, 5360–5366. [CrossRef]

68. Riek, R.; Wider, G.; Pervushin, K.; Wuthrich, K. Polarization transfer by cross-correlated relaxation in solution NMR with very large molecules. *Proc. Natl. Acad. Sci. USA* 1999, 96, 4918–4923. [CrossRef]

69. Takeuchi, K.; Arthanari, H.; Shimada, I.; Wagner, G. Nitrogen detected TROSY at high field yields high resolution and sensitivity for protein NMR. *J. Biomol. NMR* 2016, 64, 143–151. [CrossRef]

70. Takeuchi, K.; Arthanari, H.; Imai, M.; Wagner, G.; Shimada, I. Nitrogen-detected TROSY yields comparable sensitivity to proton-detected TROSY for non-deuterated, large proteins under physiological salt conditions. *J. Biomol. NMR* 2016, 64, 143–151. [CrossRef]

71. Marion, D.; Ikura, M.; Tschudin, R.; Bax, A. Rapid recording of 2D NMR spectra without phase cycling. Application to the study of hydrogen exchange in proteins. *J. Magn. Reson.* 1989, 85, 393–399. [CrossRef]

72. Krapp, S.; Mimura, Y.; Jefferis, R.; Huber, R.; Sondermann, P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. *J. Mol. Biol.* 2003, 325, 979–989. [CrossRef]

73. Sifniotis, V.; Cruz, E.; Eroglu, B.; Kayser, V. Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation. *Antibodies* 2019, 8, 36. [CrossRef] [PubMed]

74. Leung, D.; Wurst, J.M.; Liu, T.; Martinez, R.M.; Datta-Mannan, A.; Feng, Y. Antibody Conjugates-Recent Advances and Future Innovations. *Antibodies* 2020, 9, 2. [CrossRef] [PubMed]

75. Yanaka, S.; Yamazaki, T.; Yogo, R.; Noda, M.; Uchiyama, S.; Yagi, H.; Kato, K. NMR Detection of Semi-Specific Antibody Interactions in Serum Environments. *Molecules* 2017, 22, 1619. [CrossRef] [PubMed]